Nevro announces publication of data from study of 10 kHz Therapy

Nevro announced the publication of new data validating the health economic benefits of 10 kHz Therapy, Nevro’s proprietary high-frequency,10 kHz spinal cord stimulation therapy. This data was derived from studies and analyses that evaluated health care utilization – doctor visits, medical procedures, tests and emergency room visits, and medication costs – and related cost data, including inpatient and outpatient service, medication, and out-of-pocket costs. Results from a study evaluating the effect of 10 kHz Therapy on resources needed to manage and care for patients with painful diabetic neuropathy were published in the Journal of Managed Care & Specialty Pharmacy. Study participants were randomly assigned to 10 kHz Therapy or conventional medical management, with outcomes measured at six months. Results showed that the 10 kHz Therapy arm experienced about half the mean rate of hospitalizations per patient compared to the CMM group (0.08 vs. 0.15). Additionally, the CMM group’s total healthcare costs per patient were approximately 51% higher compared to the 10 kHz Therapy group (equivalent to a mean annual cost per patient of $9,532 vs. $6,300).